{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-050485","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2025-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.723456+00:00","generated_at":"2026-05-23T22:43:41.587220+00:00","sec_items":["3.02","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tivic Health exercises option for Neutropenia license; accelerates $500K milestone","bullets":["Exercised Exclusive Option on March 28, 2025 to license Neutropenia indication of Entolimod from Statera.","Accelerated first milestone payment of $500,000 for IND and Phase 2 study for Neutropenia.","Issued 55,704 common shares and 131.1267 Series A Preferred shares to Statera and Avenue as consideration.","Obligated to develop Neutropenia indication at own cost and pay future milestones up to $2.75M for this indication."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-050485","json":"https://secwatch.observer/filing/0000950170-25-050485.json","markdown":"https://secwatch.observer/filing/0000950170-25-050485.md","text":"https://secwatch.observer/filing/0000950170-25-050485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025050485/0000950170-25-050485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025050485/tivc-20250328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T22:43:41.587220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}